Covance and Definiens Collaborate to Integrate Digital Pathology into Precision Medicine Design and Development
Alliance intended to establish image analysis-enabled companion diagnostics as standard for comprehensive targeted therapies
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005206/en/
Companion diagnostics are used in conjunction with targeted drugs and therapies to identify patients who are likely to benefit from a specific treatment regimen or who may have increased risk for certain side effects. The companies expect the first application of these processes will be in oncology, particularly immuno-oncology.
LabCorp and Covance have been involved in the development of drugs and their associated companion diagnostics for more than 20 years and have supported approximately two-thirds of all
The collaboration will initially focus on multiplex immunohistochemistry (IHC) and in situ hybridization (ISH) applications in early-stage clinical programs, which allow researchers to obtain significantly more information from a single sample than with other standard methods. This approach is designed to enable the therapy to advance more quickly to pivotal clinical trial scale studies. Terms of the agreement have not been disclosed.
“This collaboration unites Definiens’ ground-breaking technology and innovation with Covance’s extensive experience in biomarker identification and companion diagnostics development,” said
“Based on years of AI development, Definiens Tissue Phenomics® is recognized as the premier technology for characterizing the tumor microenvironment for immuno-oncology applications,” said
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over
This press release contains forward-looking statements about the Company’s future operations. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended
About Definiens
Definiens is a member of the
Please visit www.definiens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005206/en/
Source:
LabCorp
Investors:
Scott Frommer, +1-336-436-5076
[email protected]
or
Media:
Sue Maynard, +1-336-436-8263
[email protected]
or
Definiens
Media:
Adrian Arechiga, +49 173 2495058
[email protected]